Pancreatic cancer mRNA vaccine — exciting clinical trial results
BioNTech’s pancreatic cancer mRNA vaccine candidate, cevumeran, has shown promising results in a phase 1 trial, offering hope in cancer treatment. Individualized to each patient, it enhances immune response post-surgery and may prevent recurrence. A forthcoming phase 2 trial aims… Read More »Pancreatic cancer mRNA vaccine — exciting clinical trial results









